PubRank

Baohui Han

Author PubWeight™ 104.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 46.35
2 Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012 2.98
3 A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 2011 2.85
4 Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol 2015 2.14
5 Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet 2012 1.49
6 Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006 1.24
7 Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007 1.12
8 Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011 1.10
9 Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer 2013 1.09
10 Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2012 1.05
11 Endobronchial ultrasound-guided transbronchial needle aspiration in diagnosing intrathoracic tuberculosis. Ann Thorac Surg 2013 1.05
12 Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One 2013 1.04
13 The value of autofluorescence bronchoscopy combined with white light bronchoscopy compared with white light alone in the diagnosis of intraepithelial neoplasia and invasive lung cancer: a meta-analysis. J Thorac Oncol 2011 1.04
14 Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res 2009 1.00
15 Prognostic significance of OCT4 expression in adenocarcinoma of the lung. Jpn J Clin Oncol 2010 0.94
16 Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer 2014 0.92
17 A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2013 0.92
18 IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance. Tumour Biol 2013 0.91
19 Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin J Cancer Res 2013 0.91
20 Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma. Med Oncol 2015 0.91
21 TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer 2009 0.90
22 Genome-wide association study identifies a novel susceptibility locus at 12q23.1 for lung squamous cell carcinoma in han chinese. PLoS Genet 2013 0.90
23 Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer 2013 0.89
24 The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. Am J Clin Oncol 2013 0.88
25 VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer. J Thorac Dis 2013 0.88
26 Retracted MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer. Tumour Biol 2014 0.88
27 Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Tumour Biol 2014 0.88
28 Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients. Med Oncol 2015 0.87
29 Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS One 2012 0.87
30 A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 2012 0.87
31 Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol 2012 0.86
32 XPA gene rs1800975 single nucleotide polymorphism and lung cancer risk: a meta-analysis. Tumour Biol 2014 0.86
33 [Chinese guidelines on the diagnosis and treatment of primary lung cancer 
(2011 version)]. Zhongguo Fei Ai Za Zhi 2012 0.86
34 Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells. Med Oncol 2015 0.85
35 Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Oncologist 2012 0.85
36 Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population. J Clin Lab Anal 2012 0.85
37 Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Cell Biochem Biophys 2014 0.84
38 [Preoperative induction chemotherapy for resectable stage IIIA non-small-cell lung cancer: a meta-analysis of 13 double-blind, randomized clinical trials.]. Zhongguo Fei Ai Za Zhi 2008 0.84
39 [Survival analysis of 1,742 patients with stage IV non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2011 0.84
40 Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patients. Cell Physiol Biochem 2014 0.83
41 [Surgical treatment for non-small cell lung cancer patients with synchronous solitary brain metastasis]. Zhongguo Fei Ai Za Zhi 2013 0.82
42 Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines 2007 0.82
43 Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of non-lymph node thoracic lesions. Ann Thorac Med 2013 0.80
44 Gprc5a-deficiency confers susceptibility to endotoxin-induced acute lung injury via NF-κB pathway. Cell Cycle 2015 0.80
45 Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer 2014 0.80
46 Vitamin D inhibition of lung adenocarcinoma cell proliferation in vitro. Tumour Biol 2014 0.79
47 ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer. Exp Ther Med 2011 0.79
48 [The Clinical Analysis of 21 Patients with Lymphoepithelioma-like Carcinoma after Operation.]. Zhongguo Fei Ai Za Zhi 2009 0.79
49 Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Cancer Sci 2012 0.78
50 EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer. Mol Cancer 2014 0.78
51 NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. Tumour Biol 2013 0.78
52 [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China]. Zhongguo Fei Ai Za Zhi 2012 0.77
53 [Preliminary results of metabolite in serum and urine of lung cancer patients detected by metabolomics]. Zhongguo Fei Ai Za Zhi 2012 0.77
54 [Role of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma]. Zhongguo Fei Ai Za Zhi 2010 0.77
55 [The clinical analysis of paclitaxel at two dose levels plus carboplatin as the first-line treatment in advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2011 0.77
56 [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas]. Zhongguo Fei Ai Za Zhi 2013 0.77
57 Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. Oncol Lett 2012 0.77
58 Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol 2014 0.77
59 Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. Chest 2012 0.77
60 [Correlations between OCT4 expression and clinicopathological factors and prognosis of patients with lung adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2013 0.77
61 [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases]. Zhongguo Fei Ai Za Zhi 2010 0.76
62 Placental Growth Factor Promotes Metastases of Non-Small Cell Lung Cancer Through MMP9. Cell Physiol Biochem 2015 0.76
63 [Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2004 0.76
64 Cytotoxic T lymphocyte-dependent tumor growth inhibition by a vascular endothelial growth factor-superantigen conjugate. Biochem Biophys Res Commun 2012 0.75
65 Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy. Cancer 2011 0.75
66 [The clinical analysis of first-line palitaxel plus platinum-based chemotherapy to treat elderly non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
67 [The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance.]. Zhongguo Fei Ai Za Zhi 2009 0.75
68 [Target therapy for lung cancer: more hope and more choice]. Zhongguo Fei Ai Za Zhi 2005 0.75
69 [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi 2011 0.75
70 [Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
71 Endobronchial Ultrasound Elastography for Evaluation of Intrathoracic Lymph Nodes: A Pilot Study. Respiration 2017 0.75
72 [Advances in bevacizumab therapy of primary lung cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
73 [The biologic characteristics and treatment of non-small cell lung cancer in non smokers.]. Zhongguo Fei Ai Za Zhi 2009 0.75
74 Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study. Med Oncol 2015 0.75
75 [Protein kinase C inhibitor and treatment of non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
76 [Analysis of prognostic factors in 352 lung cancer patients with brain metastases.]. Zhongguo Fei Ai Za Zhi 2008 0.75
77 [Clinical Observation of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer: A Report of 92 Eases.]. Zhongguo Fei Ai Za Zhi 2009 0.75
78 [New argument for cycle of chemotherapy in advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2004 0.75
79 [Analysis of prognostic factors in patients with stage IV lung adenocarcinoma after failure of second-line EGFR-TKIs therapy]. Zhongguo Fei Ai Za Zhi 2013 0.75
80 [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. Zhongguo Fei Ai Za Zhi 2011 0.75
81 [Paclitaxel blocks immunologic escape through up-regulating TAP-1, TAP-2 and eliminatiing Treg cells in 3LL-bearing mice]. Zhongguo Fei Ai Za Zhi 2010 0.75
82 [Decline of dendritic cells in the peripheral blood of patients with non-small cell lung cancer and its relation to vascular endothelial growth factor]. Zhongguo Fei Ai Za Zhi 2002 0.75
83 [Prognostic Analysis of ERCC1, RRM1 and p53 Expressions in Postoperative Stage I-II Lung Cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
84 [Effects of protein kinase C inhibitor,chelerythrine chloride,on drug-sensitivity of NSCLC cell lines]. Zhongguo Fei Ai Za Zhi 2007 0.75
85 [Analysis of Subclassification by Size and Survival-associated Factors of Stage I Non-small Cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
86 [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2011 0.75
87 [The changes of the first-line chemotherapy on advanced non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi 2008 0.75
88 [Roles of novel antiangiogenetic agents in non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi 2008 0.75
89 [Research advance on molecular biology of lung cancer metastasis.]. Zhongguo Fei Ai Za Zhi 2008 0.75
90 [Multivariate survival analysis of patients with stage I NSCLC]. Zhongguo Fei Ai Za Zhi 2011 0.75
91 [Establishment of a predicting model to evaluate the probability of malignancy or benign in patients with solid solitary pulmonary nodules]. Zhonghua Yi Xue Za Zhi 2016 0.75
92 Navigation Bronchoscopy-Guided Radiofrequency Ablation for Nonsurgical Peripheral Pulmonary Tumors. Respiration 2017 0.75
93 [Effects of EGFR-TKIs on sequential pemetrexed
for advanced pulmonary adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2012 0.75
94 [Taxol-resistant Non-small cell lung cancer and microtubulin.]. Zhongguo Fei Ai Za Zhi 2008 0.75
95 Comparison of PG-SGA, SGA and body-composition measurement in detecting malnutrition among newly diagnosed lung cancer patients in stage IIIB/IV and benign conditions. Med Oncol 2010 0.75
96 Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. Sci Rep 2016 0.75
97 [Advances of maintenance therapy on advanced non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
98 [The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
99 [Research advance on non-small cell lung carcinoma with neuroendocrine differentiation]. Zhongguo Fei Ai Za Zhi 2011 0.75